Increased circulating CD14brightCD16+ intermediate monocytes are regulated by TNF-α and IL-6 axis in accordance with disease activity in patients with rheumatoid arthritis.

Authors:
Masako Tsukamoto
Masako Tsukamoto
Graduate School of Pharmaceutical Sciences
Japan
Katsuya Suzuki
Katsuya Suzuki
Saitama Medical University
Japan
Noriyuki Seta
Noriyuki Seta
Keio University School of Medicine

Clin Exp Rheumatol 2018 Jul-Aug;36(4):540-544. Epub 2018 Jan 31.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Objectives: Although circulating CD14brightCD16+ monocyte subsets are increased in inflammatory disease, the pathogenesis of the increase in the inflammatory condition of the cells is still unclear and the relationship to cytokines is unknown particularly in rheumatoid arthritis (RA). The purpose of this study was to investigate the influence anti-cytokine treatment has on CD14brightCD16+ monocytes in patients with RA.

Methods: Thirty-two RA patients and 14 healthy volunteers (HV) were enrolled in this study. All the patients had never been treated with methotrexate (MTX) or biological agents. Peripheral blood samples and clinical information of the patients were obtained at the time of 0, 12 and 24 weeks of treatment. Peripheral blood samples were also obtained from the HV. The expression levels of CD14 and CD16 on monocytes were measured by flow cytometry (FCM).

Results: Eight patients received anti-interleukin (IL)-6 receptor antibody, tocilizumab (TCZ) treatment alone, 12 patients received anti-tumour necrosis factor (TNF)-α antibody, adalimumab (ADA) with MTX treatment and the others received only MTX treatment. FCM analysis revealed that the proportion of CD14brightCD16+ monocytes significantly increased in patients at baseline compared with HV. The proportion of CD14brightCD16+ monocytes significantly decreased after TCZ, and ADA with MTX treatment. The proportion of intermediate monocytes was significantly and positively correlated with disease activity and it improved in accordance with the proportion of CD14brightCD16+ monocytes after inhibition of signal transduction of inflammatory cytokines.

Conclusions: We showed that the population of CD14brightCD16+ monocytes significantly decreased with the change of disease activity by key cytokines, IL-6 or TNF-α signal blockade in RA. This result indicates that the proportion of those monocytes is important for reflecting disease activity in RA.
September 2018
8 Reads

Publication Analysis

Top Keywords

cd14brightcd16+ monocytes
20
disease activity
16
proportion cd14brightcd16+
12
mtx treatment
12
monocytes
9
rheumatoid arthritis
8
patients received
8
patients
8
peripheral blood
8
monocytes decreased
8
blood samples
8
ada mtx
8
intermediate monocytes
8
circulating cd14brightcd16+
8
cd14brightcd16+
7
treatment
6
proportion
5
disease
5
monocytes inhibition
4
levels cd14
4

Similar Publications

CD14CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis.

Arthritis Res Ther 2017 Feb 10;19(1):28. Epub 2017 Feb 10.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Background: Three different subsets of circulating human monocytes, CD14CD16- (classical), CD14CD16+ (intermediate), and CD14CD16+ (non-classical) have been recently identified. It has been reported that CD14CD16+ monocytes are increased in rheumatoid arthritis (RA). However, the role of each monocyte subset in the pathogenesis of RA is still unclear. Read More

View Article
February 2017

Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.

Pharmacol Res 2016 05 1;107:308-314. Epub 2016 Apr 1.

Department of Health Sciences, School of Medicine, University of Eastern Piedmont, Via Solaroli, 17-28100 Novara, Italy; IRCAD, School of Medicine, Novara, Italy. Electronic address:

Circulating human monocytes, a functionally and phenotypically heterogeneous population, are emerging as fundamental cell types in rheumatoid arthritis (RA). The aim of this pilot study was to assess the correlation, if any, among anti-rheumatic drug therapy, circulating CD14(+)CD16(+) monocytes and validated clinical scales (e.g. Read More

View Article
May 2016

FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy.

PLoS One 2012 3;7(1):e28918. Epub 2012 Jan 3.

NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom.

Objective: The expression of FcγRIIIa/CD16 may render monocytes targets for activation by IgG-containing immune complexes (IC). We investigated whether FcγRIIIa/CD16 was upregulated in rheumatoid arthritis (RA), associated with TNF production in response to IC-stimulation, and if this predicted response to methotrexate therapy.

Methods: FcγRIIIa/CD16 expression on CD14(low) and CD14++ monocytes was measured by flow cytometry in healthy controls and RA patients (early and long-standing disease). Read More

View Article
May 2012

Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.

Clin Exp Immunol 2012 Oct;170(1):36-46

NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK.

Anti-tumour necrosis factor (TNF) biologics have revolutionized therapy of rheumatoid arthritis (RA). We compared the effects of infliximab on numbers of circulating leucocyte subsets in early RA (disease/symptom duration of ≤1 year) and late RA patients (>1 year). A control group consisted of early RA patients treated with a combination of methotrexate (MTX) and methylprednisolone. Read More

View Article
October 2012